Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended July 3, 2009
Business Overview: Greatbatch is a developer and manufacturer of critical products for medical devices (Cardiac Rhythm Management, Neuromodulation, Vascular Access, Orthopaedics) and electrochemical cells/battery packs. The company operates two segments: Greatbatch Medical and Electrochem Solutions.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 3, 2009 | Six Months Ended July 3, 2009 | Six Months Ended June 27, 2008 |
|---|---|---|---|
| Sales | $134,725 | $274,543 | $263,802 |
| Gross Profit | $41,472 | $85,636 | $67,294 |
| Gross Margin | 30.8% | 31.2% | 25.5% |
| Operating Income | $12,469 | $27,268 | $7,212 |
| Operating Margin | 9.3% | 9.9% | 2.7% |
| Net Income | $6,562 | $13,226 | $268 |
| Diluted EPS | $0.28 | $0.56 | $0.01 |
| Cash and Cash Equivalents | $19,003 (End of Period) | N/A | |
| Net Cash from Operating Activities | N/A | $21,736 | $27,363 |
| Total Debt (Current + Long-term) | $307,829 | N/A | |
| Working Capital | $134,521 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales for the six months ended July 3, 2009, increased 4% to $274.5 million compared to $263.8 million in the prior year. This was driven by a 14% increase in CRM/Neuromodulation sales and a full six months of Orthopaedic operations, partially offset by a 15% decline in Electrochem sales due to energy market slowdowns.
- Profitability Surge: Operating income increased significantly to $27.3 million (6 months 2009) from $7.2 million (6 months 2008). This improvement is attributed to reduced acquisition-related charges and consolidation costs ($5.2 million in 2009 vs. $12.6 million in 2008) and manufacturing efficiencies.
- Margin Expansion: Gross margin improved to 31.2% from 25.5% year-over-year, driven by manufacturing efficiencies at the Tijuana facility and favorable foreign currency impacts (stronger USD vs. Mexican Peso).
- Accounting Change: The company adopted FSP APB 14-1 regarding convertible debt, requiring retrospective restatement of 2008 figures. This adjustment increased reported interest expense and reduced prior period net income.
Guidance, Outlook, and Risks
- 2009 Sales Outlook: Management projects full-year 2009 sales in the range of $550 million to $600 million. This assumes continued growth in CRM/Neuromodulation but acknowledges risks from softening Orthopaedic and Electrochem markets, potential delays in elective surgeries, and foreign exchange fluctuations.
- Cost Initiatives: The company is executing facility shutdowns and consolidations (2007 & 2008 initiatives) with total expected costs of $14.2 million to $17.5 million. Approximately $12.4 million has been incurred through July 3, 2009.
- Liquidity: As of July 3, 2009, the company held $19.0 million in cash and had $114 million available under its revolving credit facility. Management expects cash flow from operations to be sufficient to meet operating needs and fund debt repayments.
- Key Risks:
- Customer Concentration: Four customers accounted for 63% of sales in the second quarter of 2009.
- Litigation: An ongoing patent infringement case (Pressure Products) resulted in a $1.1 million jury award; the company is appealing and has accrued $1.2 million in escrow. A separate 2002 lawsuit carries a potential risk of loss up to $2.5 million.
- Debt Covenants: The company must maintain an adjusted EBITDA to interest expense ratio of at least 3.00:1 and a leverage ratio not exceeding 5.00:1 (reducing to 4.50:1 after Sept 2009). The company was in compliance as of July 3, 2009.
Investor Verification Checklist
- Debt Maturity: Verify the repayment plan for the $30.5 million of convertible subordinated notes (CSN I) classified as current liabilities due to a put option exercisable in June 2010.
- Orthopaedic Segment: Monitor the Orthopaedic segment closely, as it faces headwinds from foreign currency impacts, delayed product launches, and the elective nature of surgeries.
- Electrochem Recovery: Assess the timeline for recovery in the Electrochem segment, which is currently depressed by lower oil prices and healthcare industry uncertainty.
- Litigation Resolution: Track the outcome of the Pressure Products appeal and the 2002 proprietary information lawsuit, as unfavorable rulings could impact earnings.
- Consolidation Savings: Confirm that the ongoing facility consolidation initiatives deliver the projected cost savings to sustain the improved operating margins.